TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25282564

Group type: EXPERIMENTAL
Intervention: Moisturizer applied daily during the first 32 weeks of life
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no moisturizer)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Moisturizer
Number of subjects: 59

Group type: COMPARATOR
Intervention: Infants with AD/eczema
Number of subjects: 59
Study: 21803547

Group type: EXPERIMENTAL
Intervention: Corticosteroid alone
Number of subjects: 81

Group type: COMPARATOR
Intervention: Inhaled corticosteroid/bronchodilator therapy (continuing treatment)
Number of subjects: 81
Study: 20212319

Group type: EXPERIMENTAL
Intervention: Adapted logrank test for cause-specific mortality
Number of subjects: 41224

Group type: COMPARATOR
Intervention: All-cause mortality analysis
Number of subjects: 41224

Group type: COMPARATOR
Intervention: Naive cause-specific logrank test
Number of subjects: 41224
Study: 17697829

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate/hydralazine (ID/H) taken for an additional 209 ± 116 days
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate/hydralazine (ID/H)
Number of subjects: 198
Study: 16390805

Group type: EXPERIMENTAL
Intervention: Phenobarbital 20 mg/kg IV
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 45
Study: 12566747

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood collection before placental detachment (group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Umbilical cord blood collection after placental delivery (group B)
Number of subjects: 47
Study: 9585793

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml double-strength, three times a day for 2 days)
Number of subjects: 10
Study: 7658286

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation, large doses (exact dosage not specified)
Number of subjects: 0
Study: 2670423

Group type: EXPERIMENTAL
Intervention: 0.5 mg norethindrone and 0.035 mg ethinyl estradiol (NET + EE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3 mg norgestrel and 0.03 mg ethinyl estradiol (Ng + EE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NET + EE
Number of subjects: 0
Study: 1138664

Group type: EXPERIMENTAL
Intervention: Bretylium Tosylate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 31
Study: 31345107

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d, n=31)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Perindopril (5 mg/d, n=31)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Lifestyle modification (n=31)
Number of subjects: 93
Study: 31092660

Group type: EXPERIMENTAL
Intervention: Brief mental health intervention delivered by lay health workers in primary care services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-sharing approaches to integrating services for common mental disorders with HIV and diabetes primary care services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost utility analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider and patient cost per patient year for each study arm and chronic disease
Number of subjects: 0
Study: 28430522

Group type: EXPERIMENTAL
Intervention: Naturalistic lighting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lighting (Control)
Number of subjects: 0
Study: 25746727

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (containing vitamin B1, B2, niacin, B6, B12, folic acid, C, carnitine, coenzyme Q10, naïve galacto-oligosaccharide, and zinc) for 12 weeks after each dialysis session.
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation for 12 weeks.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks after each dialysis session.
Number of subjects: 202
Study: 23176986

Group type: EXPERIMENTAL
Intervention: sufentanil 5.0 μg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: morphine 100 μg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: clonidine 75 μg
Number of subjects: 96

Group type: COMPARATOR
Intervention: no adjuvant (Group I)
Number of subjects: 96
Study: 19948385

Group type: EXPERIMENTAL
Intervention: MF11RCE (80mg red clover isoflavones)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 18720713

Group type: EXPERIMENTAL
Intervention: Antidepressant coaxil during perioperative period (6 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no coaxil treatment)
Number of subjects: 61
Study: 16505759

Group type: EXPERIMENTAL
Intervention: Repeated large volume paracentesis plus intravenous albumin (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination of clonidine (0.075 mg twice daily) and spironolactone (200 to 400 mg daily) (group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination of clonidine and spironolactone (group 2)
Number of subjects: 20
Study: 12450445

Group type: EXPERIMENTAL
Intervention: Weekly fructosamine testing (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care of daily glucose (Group 2)
Number of subjects: 60
Study: 10352786

Group type: EXPERIMENTAL
Intervention: Dopamine (2 micrograms/kg per min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopexamine (0.5 microgram/kg per min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopexamine
Number of subjects: 20
Study: 7795502

Group type: EXPERIMENTAL
Intervention: High dose alcohol (80 mg/100 ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low dose alcohol (40 mg/100 ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Expecting alcohol with high dose alcohol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo with expectancy of alcohol
Number of subjects: 90
Study: 1646259

Group type: EXPERIMENTAL
Intervention: High-salt diet (260 mmol NaCl/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-salt diet (20 mmol NaCl/day)
Number of subjects: 23
Study: 7025168

Group type: EXPERIMENTAL
Intervention: 30 mg/kg body weight as a single dose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 40 mg/kg as a single dose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 25 mg/kg, twice a day at a 6-hour interval
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: All dosages
Number of subjects: 138
Study: 28881147

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) cycling
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive leg cycling
Number of subjects: 11
Study: 26243373

Group type: EXPERIMENTAL
Intervention: Anti-tuberculosis therapy plus Silybum marianum capsule
Number of subjects: 370

Group type: COMPARATOR
Intervention: Anti-tuberculosis therapy plus vitamin C tablet
Number of subjects: 370
Study: 24576517

Group type: EXPERIMENTAL
Intervention: Extended administration of oral betrixaban (35‐42 days)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard short course of prophylaxis with subcutaneous enoxaparin (10 ± 4 days followed by placebo)
Number of subjects: 1000
Study: 22510506

Group type: EXPERIMENTAL
Intervention: Feiji Decoction for soothing the liver combined with psychotherapy and chemotherapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 118
Study: 20731638

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 18400357

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day (RG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study: 16402568

Group type: EXPERIMENTAL
Intervention: Allopurinol (ALLO, n = 31)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Itraconazole (ITRA, n = 23)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 12606175

Group type: EXPERIMENTAL
Intervention: Behavioural interventions alone (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural and STI interventions (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine government health services and community development activities (group C)
Number of subjects: 0
Study: 10575655

Group type: EXPERIMENTAL
Intervention: Etomoxir (ETO) 75 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Etomoxir (ETO) 150 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8688226

Group type: EXPERIMENTAL
Intervention: Concurrent external radiation therapy (70 Gy/39 fractions/8 weeks) and chemotherapy with cisplatin (50 mg/m2 in short infusion, D1, D15, D29, D43) and fluorouracil (5 mg/kg, intra-muscular, every Monday, Wednesday and Friday)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Radiotherapy alone with the same modalities
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Experimental group (non responders to induction chemotherapy)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (non responders to induction chemotherapy)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Experimental group (responders to induction chemotherapy)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (responders to induction chemotherapy)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 1770421

Group type: EXPERIMENTAL
Intervention: Group 1: Dentifrice with 0.075% sanguinaria extract and 2.0% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group 3: Dentifrice with 0.8% sodium monofluorophosphate, 0.075% sanguinaria extract, and 0.05% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Group 2 and Group 4: identical products without sanguinaria extract or zinc chloride).
Number of subjects: 120
Study: 7052184

Group type: EXPERIMENTAL
Intervention: Discussion group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Activity group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ECT treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Discussion group and Activity group
Number of subjects: 38
Study: 30514777

Group type: EXPERIMENTAL
Intervention: MGMT methylation status (unmethylated, gray zone, methylated)
Number of subjects: 4041

Group type: EXPERIMENTAL
Intervention: MGMT assay
Number of subjects: 4041
Study: 29110641

Group type: EXPERIMENTAL
Intervention: Lifestyle modification and peer support home blood pressure monitoring
Number of subjects: 0
Study: 26205609

Group type: EXPERIMENTAL
Intervention: Providing an up-to-date medical information sheet about BRCA1/2 genetic topics and a photograph with the names of the researchers
Number of subjects: 235

Group type: COMPARATOR
Intervention: Providing a leaflet about aggregate psychosocial research results
Number of subjects: 235
Study: 23917472

Group type: EXPERIMENTAL
Intervention: Shortened stride length
Number of subjects: 19

Group type: COMPARATOR
Intervention: Greater stride length
Number of subjects: 19
Study: 22001911

Group type: COMPARATOR
Intervention: Normoxic (NM: 21% FIO2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acute hypoxic (HY: 13% FIO2)
Number of subjects: 20
Study: 19161480

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Faculty staff-led training
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 89
Study: 17541944

Group type: EXPERIMENTAL
Intervention: MPS160 in incomplete Freund adjuvant (Montanide ISA‐51)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MPS160 in Montanide ISA‐51 with 75 microg of granulocyte‐macrophage‐stimulating factor (GM‐CSF)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MPS160 in Montanide ISA‐51 with 100 microg of GM‐CSF
Number of subjects: 28
Study: 15808922

Group type: EXPERIMENTAL
Intervention: Intravenous (iv) ghrelin administration (1.0 microg/kg) in bulimia nervosa (BW)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous (iv) ghrelin administration (1.0 microg/kg) in healthy women (HW)
Number of subjects: 16
Study: 11920413

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pamidronate 10 mg
Number of subjects: 84
Study: 10354910

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) at 5.0 hPa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-expiratory positive pressure (NPEP)
Number of subjects: 0
Study: 7743622

Group type: EXPERIMENTAL
Intervention: Higher-intensity, home-based exercise (3 sessions/week, 40 minutes at 73%-88% peak heart rate)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Lower-intensity, home-based exercise (5 sessions/week, 30 minutes at 60%-73% peak heart rate)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Higher-intensity, group-based exercise (3 sessions/week, 40 minutes at 73%-88% peak heart rate)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 269
Study: 2254718

Group type: EXPERIMENTAL
Intervention: Normal milk (1180 mg Ca2+, 1650 mg K+, 110 mg Mg2+ d‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mineral-poor milk (95 mg Ca2+, 580 mg K+, 10 mg Mg2+ d‐1)
Number of subjects: 0
Study: 7410779

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 31792321

Group type: EXPERIMENTAL
Intervention: Deep Variational Autoencoder (VAE)
Number of subjects: 3832

Group type: COMPARATOR
Intervention: Point-wise (PW) regression
Number of subjects: 3832
Study: 27750388

Group type: EXPERIMENTAL
Intervention: T4‐like coliphage cocktail
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Commercial phage preparation (Coliproteus from Microgen/Russia)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Oral rehydration therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Coliphage preparations or placebo
Number of subjects: 109
Study: 25678311

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention consisting of physical fitness training combined with counselling sessions focusing on physical behaviour and sports participation.
Number of subjects: 57

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 57
Study: 22840185

Group type: EXPERIMENTAL
Intervention: Training care staff to observe and identify signs of awareness in residents (n = 32) over an eight-week period
Number of subjects: 65

Group type: COMPARATOR
Intervention: No training for care staff (n = 33)
Number of subjects: 65
Study: 21786113

Group type: EXPERIMENTAL
Intervention: Silymarin-based cream (Leviaderm(®))
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 101
Study: 19138415

Group type: EXPERIMENTAL
Intervention: IVF after 6 cycles of unsuccessful IUI
Number of subjects: 103

Group type: COMPARATOR
Intervention: Immediate IVF without preceding IUI
Number of subjects: 103
Study: 17588273

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol
Number of subjects: 92

Group type: COMPARATOR
Intervention: Manual-controlled infusion of propofol
Number of subjects: 92
Study: 15450782

Group type: COMPARATOR
Intervention: Bipolar disorder patients
Number of subjects: 239
Study: 11229823

Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation (50 U/kg) by intravenous infusion prior to incision
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9893913

Group type: EXPERIMENTAL
Intervention: Nefopam (0.15 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 30
Study: 7983646

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 71
Study: 2691569

Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2c, 10 MU/m2 body surface, twice weekly, intramuscularly for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 1090684

Group type: EXPERIMENTAL
Intervention: 2% micronized griseofulvin applied 3 times daily for 3 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1% tolnaftate cream
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 52
Study: 30593974

Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment (CAST)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Physical health education training (control)
Number of subjects: 91
Study: 28549145

Group type: EXPERIMENTAL
Intervention: Combined lots of rVSVΔG‐ZEBOV‐GP (2 × 10^7 pfu, n = 797)
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: High-dose rVSVΔG‐ZEBOV‐GP (1 × 10^8 pfu, n = 264)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Placebo (n = 133)
Number of subjects: 1197
Study: 25983669

Group type: EXPERIMENTAL
Intervention: Montmorency cherry juice (CJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 24192410

Group type: EXPERIMENTAL
Intervention: Photo-stimulable phosphor (PSP) plates
Number of subjects: 59

Group type: COMPARATOR
Intervention: Film
Number of subjects: 59
Study: 21550589

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) consisting of 6 sessions combining behavioural sleep medicine techniques and anxiety treatment techniques
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study: 19687350

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril (5.0/20.0 mg, 5.0/40.0 mg, 10.0/40.0 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Hydrochlorothiazide/benazepril (12.5/20.0 mg, 12.5/40.0 mg, 25.0/40.0 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Comparison of Amlodipine/benazepril vs Hydrochlorothiazide/benazepril
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril in female patients
Number of subjects: 125
Study: 16971360

Group type: EXPERIMENTAL
Intervention: Tazarotene plus hydroquinone (4% cream)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Tazarotene alone (0.1% cream)
Number of subjects: 131
Study: 14755009

Group type: EXPERIMENTAL
Intervention: Consolidation/maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11069800

Group type: EXPERIMENTAL
Intervention: Budesonide (256 microg; Rhinocort Aqua)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9263752

Group type: EXPERIMENTAL
Intervention: Calcitriol 1.5 micrograms per day for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 18
Study: 8325766

Group type: EXPERIMENTAL
Intervention: Treatment of the first seizure
Number of subjects: 498

Group type: COMPARATOR
Intervention: Treatment of recurrences
Number of subjects: 498
Study: 3828184

Group type: EXPERIMENTAL
Intervention: Right lateral position for subarachnoid analgesia
Number of subjects: 35

Group type: COMPARATOR
Intervention: Left lateral position for subarachnoid analgesia
Number of subjects: 35
Study: 28871492

Group type: EXPERIMENTAL
Intervention: Antibiotics + Probiotics (Lactobacillus rhamnosus GG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Only Antibiotics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Antibiotics + Placebo (glucose solution at 5%)
Number of subjects: 90
Study: 28361113

Group type: EXPERIMENTAL
Intervention: Standard bodyweight-based tacrolimus starting dose
Number of subjects: 203

Group type: COMPARATOR
Intervention: CYP3A5 genotype-based tacrolimus starting dose
Number of subjects: 203
Study: 26653236

Group type: EXPERIMENTAL
Intervention: Embolization of bronchial artery (BAE)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Internal medicine (control)
Number of subjects: 115
Study: 23318478

Group type: EXPERIMENTAL
Intervention: 4-month interval surveillance (group A)
Number of subjects: 744

Group type: COMPARATOR
Intervention: 12-month interval surveillance (group B)
Number of subjects: 744
Study: 20925972

Group type: EXPERIMENTAL
Intervention: Low-frequency right rTMS to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Sequential low-frequency right-sided followed by high-frequency left-sided rTMS
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Sequential low-frequency rTMS to both hemispheres
Number of subjects: 219

Group type: COMPARATOR
Intervention: Unilateral right-sided rTMS
Number of subjects: 219

Group type: COMPARATOR
Intervention: Bilateral rTMS (both forms)
Number of subjects: 219
Study: 18167382

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid 5 mg
Number of subjects: 7714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7714
Study: 16598468

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.05 mg/ml) applied topically to the filtering bleb for 5 min on the 3 days after surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: No mitomycin C applied (control group)
Number of subjects: 52
Study: 13678971

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 616

Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 616

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 616
Study: 10883563

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (men's group)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions (conjoint group)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 861
Study: 9232359

Group type: EXPERIMENTAL
Intervention: BRS-sequence method
Number of subjects: 14

Group type: COMPARATOR
Intervention: Valsalva manoeuvre
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BRS-sequence method and Valsalva manoeuvre
Number of subjects: 14
Study: 1317524

Group type: EXPERIMENTAL
Intervention: PS600 haemodialysis
Number of subjects: 15

Group type: COMPARATOR
Intervention: PS400 dialysis
Number of subjects: 15

Group type: COMPARATOR
Intervention: PS600 haemodiafiltration
Number of subjects: 15